Eveliqure announces regulatory approval to commence first clinical studies with its combined Shigella and ETEC vaccine
Eveliqure Biotechnologies today, announces that the Hungarian regulatory agency OGYÈI has approved the clinical trial for its vaccine program to prevent diarrhoeal diseases caused by Shigella and Enterotoxigenic E. coli (ETEC). Diarrhoeal diseases are the most common illnesses in the world today, with an estimated 1.7B cases annually. Affecting 30-50% of travellers visiting developing countries, this […]
Continue Reading